Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

esorubicin

A synthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	deoxyadriamycin deoxyadriamycin hydrochloride deoxydoxorubicin
Code name:	IMI-58
Chemical structure:	4'-deoxyadriamycin hydrochloride 4'deoxydoxorubicin
NSC code:	267469

esorubicin

Search NCI's Drug Dictionary